WO2003035003A3 - Fused cells, methods of forming same, and therapie utilizing same - Google Patents

Fused cells, methods of forming same, and therapie utilizing same Download PDF

Info

Publication number
WO2003035003A3
WO2003035003A3 PCT/US2002/034287 US0234287W WO03035003A3 WO 2003035003 A3 WO2003035003 A3 WO 2003035003A3 US 0234287 W US0234287 W US 0234287W WO 03035003 A3 WO03035003 A3 WO 03035003A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
same
therapie
electrofused
dcs
Prior art date
Application number
PCT/US2002/034287
Other languages
French (fr)
Other versions
WO2003035003A2 (en
Inventor
Suyu Shu
Original Assignee
Cleveland Clinic Foundation
Suyu Shu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation, Suyu Shu filed Critical Cleveland Clinic Foundation
Priority to AU2002353890A priority Critical patent/AU2002353890A1/en
Publication of WO2003035003A2 publication Critical patent/WO2003035003A2/en
Publication of WO2003035003A3 publication Critical patent/WO2003035003A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system

Abstract

A method and apparatus for electrofusing a plurality of cancer cell types to dendritic cells (DCs) which results in the formation of electrofused DC-tumor cells with high efficiency and high viability. The method comprises subjecting the cells with multiple pulses of voltage in specially designed media. This is the first documentation of electrofusion of large numbers of DCs and tumor cells. Evidence demonstrates those cells contain all essential DC molecules and express tumor antigens. A single vaccination of animals with pre-existing tumors results in substantial erradication of tumors and cure of animals. The electrofused-cells can be used immediately. These fusion hybrids are to be used for the treatment of cancer directly as vaccines or indirectly by activating immune lymphocytes for adoptive immunotherapy.
PCT/US2002/034287 2001-10-26 2002-10-25 Fused cells, methods of forming same, and therapie utilizing same WO2003035003A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002353890A AU2002353890A1 (en) 2001-10-26 2002-10-25 Fused cells, methods of forming same, and therapie utilizing same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34802601P 2001-10-26 2001-10-26
US60/348,026 2001-10-26

Publications (2)

Publication Number Publication Date
WO2003035003A2 WO2003035003A2 (en) 2003-05-01
WO2003035003A3 true WO2003035003A3 (en) 2003-10-16

Family

ID=23366352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034287 WO2003035003A2 (en) 2001-10-26 2002-10-25 Fused cells, methods of forming same, and therapie utilizing same

Country Status (3)

Country Link
US (1) US20030082163A1 (en)
AU (1) AU2002353890A1 (en)
WO (1) WO2003035003A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212338A1 (en) * 2000-01-11 2007-09-13 Greenville Hospital System Hybrid cells
EP2557164A1 (en) 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
EP1702065B1 (en) * 2003-12-01 2017-02-15 Cellectis Non-uniform electric field chamber for cell fusion
ATE493650T1 (en) 2006-09-05 2011-01-15 Celica Biomedical Ct D O O METHOD FOR DETERMINING THE QUANTITY AND QUALITY OF HYBRIDOMES
WO2008049113A2 (en) * 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
ES2840750T3 (en) * 2008-09-22 2021-07-07 Baylor College Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
AU2014236726A1 (en) 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
JP6467406B2 (en) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド Methods for inducing partial apoptosis using caspase polypeptides
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
JP6718444B2 (en) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） T cell receptors directed against Bob1 and uses thereof
CN113943712B (en) * 2021-12-20 2022-03-22 南京岚轩生物科技有限公司 Electrofusion buffer solution, preparation method thereof and electrofusion method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5390696A (en) * 1995-04-20 1996-11-07 University Of South Florida Purified and isolated sertoli cell aggregate
US5700282A (en) * 1995-10-13 1997-12-23 Zabara; Jacob Heart rhythm stabilization using a neurocybernetic prosthesis
US6073048A (en) * 1995-11-17 2000-06-06 Medtronic, Inc. Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
US5650305A (en) * 1996-05-15 1997-07-22 Health Research Inc. Method to produce hybrid cells by electrofusion
US20020041868A1 (en) * 1997-04-15 2002-04-11 Charles Nicolette Cell fusions and methods of making and using the same
WO1999064581A1 (en) * 1998-06-10 1999-12-16 University Of South Florida Electrofusion chamber
US6355485B1 (en) * 1998-06-10 2002-03-12 University Of South Florida Electrofusion chamber

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAYASHI T. ET AL.: "Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion", CLIN. IMMUNOL., vol. 104, no. 1, July 2002 (2002-07-01), pages 14 - 20, XP002963801 *
KUGLER A. ET AL.: "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", NATURE MED., vol. 6, no. 3, March 2000 (2000-03-01), pages 332 - 336, XP001005439 *
ORENTAS R.J. ET AL.: "Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine", CELL IMMUNOL., vol. 213, no. 1, 10 October 2001 (2001-10-10), pages 4 - 13, XP002963600 *
SCOTT-TAYLOR T.H. ET AL.: "Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines", BIOCHIM. BIOPHYS. ACTA, vol. 1500, no. 3, 17 March 2000 (2000-03-17), pages 265 - 279, XP001019114 *
WANG J. ET AL.: "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", J. IMMUNOL., vol. 161, 1998, pages 5516 - 5524, XP002171426 *

Also Published As

Publication number Publication date
US20030082163A1 (en) 2003-05-01
WO2003035003A2 (en) 2003-05-01
AU2002353890A1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
WO2003035003A3 (en) Fused cells, methods of forming same, and therapie utilizing same
Wagner et al. TT-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity.
Hayashi et al. Immunogenicity and therapeutic efficacy of dendritic–tumor hybrid cells generated by electrofusion
ATE349198T1 (en) COMPOSITION AND METHOD FOR CANCER ANTIGEN IMMUNOTHERAPY
CA2259140A1 (en) Method of activating dendritic cells
ATE260971T1 (en) METHOD FOR THE IN VITRO CULTIVATION OF DENDRITIC PRECURSOR CELLS AND THEIR USE FOR IMMUNOGENIC PRODUCTION
CN1592787A (en) Non-linear amplitude dielectrophoresis waveform for cell fusion
HK1046694A1 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
ATE296618T1 (en) RNA CANCER VACCINE AND METHOD OF USE THEREOF
WO2002034205A3 (en) Using heat shock proteins to increase immune response
DE69839273D1 (en) CANCER IMMUNOTHERAPY WITH SEMI-ALLOGENIC CELLS
WO1989003426A3 (en) Method of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
US20160206717A1 (en) Stimulation of immunity to endothelial cells, endothelial-like cells, and intratumor vascular channels derived from tumor tissue
ATE73349T1 (en) HEPATITIS SURFACE ANTIGEN PARTICLE VACCINATION.
Rosinski et al. Development of a minor histocompatibility antigen vaccine regimen in the canine model of hematopoietic cell transplantation
HK1057233A1 (en) Hybrid cells obtainable from antigen presenting cells
CN102827826A (en) Method for inducing dendritic cells and tumour cells to fuse
RU2000122041A (en) METHOD FOR TREATING MALIGNANT BRAIN TUMORS
WO2002043651A3 (en) Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
ATE91131T1 (en) METHOD FOR EXTRACTING MEMBRANE ANTIGENS WITH IMMUNOGENIC PROPERTIES FROM HUMAN NEOPLASTIC CELLS AND PRODUCTS SO OBTAINED.
KR20210023997A (en) Versatile CAR-T cell and its manufacturing method and its use
EP1541675A3 (en) Hybrid cells obtainable from antigen presenting cells
CN210877162U (en) Heating device for shaping blunt heads of turnbuckle bolts
CA2370278A1 (en) Chimeric lyssavirus nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP